Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Overview
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development
Aduro BioTech Inc
Bolder Biotechnology Inc
Celdara Medical LLC
Profarma
Savara Inc
Targovax ASA
XL-protein GmbH
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Drug Profiles
BBT-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMJG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GVAX Vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONCOS-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Discontinued Products
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Product Development Milestones
Featured News & Press Releases
Jul 15, 2019: Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combition with durvalumab in patients with advanced peritoneal maligncies
Jul 08, 2019: Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combition trial in Anti-PD1 refractory melanoma
Jun 12, 2019: Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmory Proteinosis (aPAP)
Jun 03, 2019: Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combition
May 23, 2019: Targovax to fully focus on ONCOS Oncolytic virus program
May 23, 2019: Targovax - approval and publication of supplemental prospectus
May 08, 2019: Savara Pharmaceuticals: Investigating GM-CSF in aPAP - A logical replacement of a dysfunctiol protein
May 08, 2019: Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma
May 06, 2019: Savara announces Molgradex received Fast Track Desigtion by FDA for treatment of autoimmune pulmory alveolar proteinosis
Apr 01, 2019: Savara initiates phase 2a clinical study of Molgradex for the treatment of NTM lung infection in people living with cystic fibrosis
Feb 11, 2019: First patient treated in dose expansion cohort of Targovax’s ONCOS-102 trial in melanoma
Dec 12, 2018: Targovax presents at DNB 9th Annual Nordic Healthcare Conference
Nov 02, 2018: Savara completes enrolment for Phase IIa Molgradex trial
Oct 24, 2018: Bolder BioTechnology to present preclinical data of BBT-007 at Acute Radiation Syndrome Meeting
Oct 15, 2018: Savara completes enrollment in pivotal Molgradex impala clinical study for the treatment of aPAP
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aduro BioTech Inc, H2 2019
Pipeline by Bolder Biotechnology Inc, H2 2019
Pipeline by Celdara Medical LLC, H2 2019
Pipeline by Profarma, H2 2019
Pipeline by Savara Inc, H2 2019
Pipeline by Targovax ASA, H2 2019
Pipeline by XL-protein GmbH, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019